- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- May 2024
- 139 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Drug Pipelines
- April 2025
- 180 Pages
Global
From €2731EUR$3,000USD£2,319GBP
- Report
- September 2021
- 40 Pages
China
From €2366EUR$2,600USD£2,010GBP
- Report
- August 2022
- 115 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- August 2020
- 80 Pages
Global
From €2503EUR$2,750USD£2,126GBP
- Report
- September 2019
- 28 Pages
Global
€9102EUR$10,000USD£7,731GBP
- Report
- March 2019
- 20 Pages
Global
€9102EUR$10,000USD£7,731GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£387GBP
Nexavar is a drug used to treat kidney cancer. It is a tyrosine kinase inhibitor, which works by blocking the action of certain proteins that are involved in the growth and spread of cancer cells. It is used in combination with other drugs to treat advanced kidney cancer. It is also used to treat liver cancer and thyroid cancer.
Nexavar is a brand name for the generic drug sorafenib. It is manufactured by Bayer AG and marketed by Onyx Pharmaceuticals. It is available in tablet form and is taken orally.
Nexavar is a widely used drug in the treatment of kidney cancer. It is used in combination with other drugs to treat advanced kidney cancer. It is also used to treat liver cancer and thyroid cancer.
Some companies in the Nexavar market include Bayer AG, Onyx Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more
